Qing Gao

Dr. Qing Gao


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2015 in RSC Advances
Verified
Journal Article
Closed access
PDF file
Yingying RenYingying Ren
Yingying Ren
QGQing Gao
Qing Gao
CZCheng Zhou
Cheng Zhou
ZWZhiyong Wei
Zhiyong Wei
YZYu Zhang
Yu Zhang
YLYang Li
Yang Li
A simple method was proposed to synthesize well-defined linear-comb highly branched poly(ε-caprolactone) with high molecular weight and narrow polydispersity.

29 January 2024 in Lupus
Verified
Journal Article
Closed access
YCYixuan Chen
Yixuan Chen
MLMeiqi Lu
Meiqi Lu
MLMengshu Lin
Mengshu Lin
QGQing Gao
Qing Gao
Objective: Hydroxychloroquine (HCQ), characterized by a broad effect on immune regulation, has been widely used in the treatment of autoimmune glomerulonephritis such as lupus nephritis (LN) and immunoglobulin A nephropathy (IgAN). The current research investigates whether HCQ plays a role in the treatment of LN and IgAN through common mechanisms since the pathogenesis of both LN and IgAN is closely related to immune complex deposition, complement activation, and ultimately inflammation. Methods: Seventy-two common targets were obtained related to the common mechanism of HCQ treatment of LN and IgAN. Targets associated with LN and IgAN were collected based on DisGeNET, GeneCards, and OMIM databases. Possible HCQ targets were obtained from the PubChem database and PharmMapper databases. The overlapping targets of HCQ ingredients, IgAN, and LN were discovered via the Venn 2.1.0 online platform. Through the DAVID database, the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted. Cytoscape (v3.9.1) was used to build a protein–protein interaction (PPI) network. Molecular docking was performed by using AutoDockTools 1.5.6 software and PyMol software to match the binding activity between HCQ and the 10 core targets. Results: The results showed that core targets (including MMP 2, PPARG, IL-2, MAPK14, MMP 9, and SRC), three signaling pathways (including the PI3K-Akt, AGE-RAGE, and MAPK), and cell differentiation (including Th1, Th2, and Th17) might be related to the body’s immunity and inflammation. These results suggested that HCQ might act on targets and pathways involved in inflammation and immune regulation to exert a common effect on the treatment of LN and IgAN. Conclusions: The current study provided new evidence for the protective mechanism and clinical utility of HCQ against LN and IgAN.

21 August 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MLMengshu Lin
Mengshu Lin
SCShengji Chen
Shengji Chen
YCYixuan Chen
Yixuan Chen
QGQing Gao
Qing Gao
IgA nephropathy (IgAN) is a prevalent primary glomerular disease and a major contributor to end-stage renal disease (ESRD). Budesonide Enteric Capsules (Nefecon®) are the first treatment approved by the U.S. Food and Drug Administration (FDA) targeting galactose-deficient IgA1 (Gd-IgA1) synthesis in the terminal ileum for IgAN. However, the detailed molecular mechanisms underlying its efficacy remain to be fully elucidated. In this study, we utilized bioinformatics approaches to integrate data from the GeneCards, CTD, and OMIM databases, identifying 787 IgAN-related targets. Additionally, we employed the PharmMapper, CTD and TargetNet databases to predict 384 budesonide targets, ultimately pinpointing 122 common targets. GO and KEGG enrichment analyses indicated that these targets are significantly enriched in biological processes such as apoptosis, inflammation responses, and cell proliferation, as well as in key pathways, including pathways in cancer, the PI3K-Akt signaling pathway, and the IL-17 signaling pathway. Protein–protein interaction (PPI) network analysis identified 10 core targets, including IL-6, TNF, AKT1, and TGF-β1, all of which exhibited strong binding affinity with budesonide in molecular docking studies. This study suggests that budesonide may exert its therapeutic effects on IgAN through multi-target and multi-pathway synergistic actions, offering valuable insights for its application in the clinical management of IgAN.

21 June 2023 in Heliyon
Verified
Journal Article
Open access
MLMeiqi Lu
Meiqi Lu
JOJuanjuan Ou
Juanjuan Ou
XDXiaoqi Deng
Xiaoqi Deng
YCYixuan Chen
Yixuan Chen
QGQing Gao
Qing Gao
Tripterygium wilfordii (TW), when formulated in traditional Chinese medicine (TCM), can effectively treat diabetic kidney disease (DKD). However, the pharmacological mechanism associated with its success has not yet been elucidated. The current work adopted network pharmacology and molecular docking for exploring TW-related mechanisms in treating DKD. Methods: In the present work, the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database was employed to obtain the effective components and candidate targets of TW. Additionally, this work utilized the UniProt protein database for screening and standardizing human-derived targets for effective components. The Cytoscape software was utilized to construct an effective component-target network for TW. Targets for DKD were acquired in the GEO, DisGeNET, GeneCards, and OMIM databases. Additionally, a Venn diagram was also plotted to select the possible targets of TW for treating DKD. Gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were conducted to explore the TW-related mechanism underlying DKD treatment. This work also built a protein-protein interaction (PPI) network based on the Cytoscape and String platform. Then, molecular docking was conducted in order to assess the affinity of key proteins for related compounds. Results: In total, 29 active components and 134 targets of TW were acquired, including 63 shared targets, which were identified as candidate therapeutic targets. Some key targets and important pathways were included in the effect of TW in treating DKD. Genes with higher degrees, including TNF and AKT1, were identified as hub genes of TW against DKD. Molecular docking showed that TNF and AKT1 bind well to the main components in TW (kaempferol, beta-sitosterol, triptolide, nobiletin, and stigmasterol). TW primarily treats DKD by acting on two targets (AKT1 and TNF) via the five active ingredients kaempferol, beta-sitosterol, triptolide, nobiletin, and stigmasterol.

1 January 2022 in The Tohoku Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MLMeiqi Lu
Meiqi Lu
LXLiangxiang Xiao
Liangxiang Xiao
BXBo Xu
Bo Xu
QGQing Gao
Qing Gao
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

1 July 2025 in Scientific Reports
Verified
Journal Article
Open access
MLMeiqi Lu
Meiqi Lu
YWYuxin Wang
Yuxin Wang
ZWZheng Wan
Zheng Wan
YCYixuan Chen
Yixuan Chen
MLMengshu Lin
Mengshu Lin
QGQing Gao
Qing Gao
According to the 2021 KDIGO guidelines, hydroxychloroquine (HCQ) had been recommended for the treatment of IgA nephropathy (IgAN). However, the precise mechanisms by which HCQ ameliorated proteinuria in IgAN were not fully understood. This study investigated the potential mechanisms of HCQ in reducing proteinuria in IgAN using network pharmacology and molecular docking approaches. Targets associated with IgAN, proteinuria, and HCQ were identified from databases including DisGeNET, GeneCards, OMIM, and PharmMapper. GO and KEGG analyses were conducted using the DAVID platform. Protein–protein interaction (PPI) networks were constructed using the STRING database, and hub genes were identified using Cytoscape software. The selection of hub genes was corroborated with data from the GEO database and validated through molecular docking. Additionally, miRNAs were predicted using NetworkAnalyst. A total of 48 genes were identified as being associated with the reduction of proteinuria in IgAN. The findings suggested that HCQ’s mechanism of action in mitigating proteinuria in IgAN primarily involved pathways related to inflammation. Furthermore, this mechanism was linked to the regulatory effects of miR-130b-3p on the expression of genes such as MMP2, IGF1, and PPARG. HCQ targeted miR-130b-3p, thereby influencing the TLR/MyD88/NF-κB signaling pathway and modulating the expression of MMP2, IGF1, and PPARG. This action may have been responsible for the observed reduction in proteinuria associated with IgAN.